BMPR1B Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O00238 |
---|---|
Clone Names | 101008251 |
Gene ID | 658 |
---|---|
Other Names | Bone morphogenetic protein receptor type-1B, BMP type-1B receptor, BMPR-1B, CDw293, BMPR1B |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | BMPR1B |
---|---|
Function | On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP7/OP-1 and GDF5. Positively regulates chondrocyte differentiation through GDF5 interaction. |
Cellular Location | Cell membrane {ECO:0000250|UniProtKB:P36898}; Single-pass type I membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the bone morphogeneticprotein (BMP) receptor family of transmembrane serine/threoninekinases. The ligands of this receptor are BMPs, which are membersof the TGF-beta superfamily. BMPs are involved in endochondral boneformation and embryogenesis. These proteins transduce their signalsthrough the formation of heteromeric complexes of 2 different typesof serine (threonine) kinase receptors: type I receptors of about50-55 kD and type II receptors of about 70-80 kD. Type II receptorsbind ligands in the absence of type I receptors, but they requiretheir respective type I receptors for signaling, whereas type Ireceptors require their respective type II receptors for ligandbinding. Mutations in this gene have been associated with primarypulmonary hypertension.
References
Mick, E., et al. J Am Acad Child Adolesc Psychiatry 49(9):898-905(2010)Joslyn, G., et al. Alcohol. Clin. Exp. Res. 34(5):800-812(2010)Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :Ma, Y., et al. J. Exp. Clin. Cancer Res. 29, 85 (2010) :Saetrom, P., et al. Cancer Res. 69(18):7459-7465(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.